NASDAQ:PTPI Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free PTPI Stock Alerts $0.64 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.63▼$0.6650-Day Range$0.63▼$1.7252-Week Range$0.60▼$5.24Volume77,209 shsAverage Volume941,111 shsMarket Capitalization$4.40 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Petros Pharmaceuticals alerts: Email Address Petros Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside525.1% Upside$4.00 Price TargetShort InterestHealthy1.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPetros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePetros Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.69% of the float of Petros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPetros Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Petros Pharmaceuticals has recently decreased by 52.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPetros Pharmaceuticals does not currently pay a dividend.Dividend GrowthPetros Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTPI. Previous Next 2.8 News and Social Media Coverage News SentimentPetros Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Petros Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for PTPI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders36.38% of the stock of Petros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.34% of the stock of Petros Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Petros Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Petros Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPetros Pharmaceuticals has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Petros Pharmaceuticals Stock (NASDAQ:PTPI)Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Read More PTPI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTPI Stock News HeadlinesApril 25, 2024 | finance.yahoo.comPetros Pharmaceuticals announces online distribution for lead ED product with Lemonaid HealthApril 23, 2024 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid HealthApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 18, 2024 | markets.businessinsider.comPositive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra DevelopmentsApril 18, 2024 | americanbankingnews.comPetros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%April 2, 2024 | markets.businessinsider.comPetros Pharma Stock Down, Despite Positive Results For Stendra StudyApril 2, 2024 | investorplace.comPTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 20, 2024 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software ProviderApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 6, 2024 | morningstar.comPetros Pharmaceuticals Inc Ordinary Shares PTPIFebruary 14, 2024 | finance.yahoo.comPetros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software ProviderJanuary 30, 2024 | uk.investing.comPetros Pharmaceuticals Inc (PTPI)January 24, 2024 | finance.yahoo.comPetros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC SwitchJanuary 17, 2024 | finance.yahoo.comPetros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC SwitchDecember 14, 2023 | markets.businessinsider.comBuy Rating on Petros Pharmaceuticals Amid Positive User Experience and Strategic FDA Pathway ComplianceDecember 12, 2023 | benzinga.comPetros Pharma Stock (NASDAQ:PTPI) Insider TradesDecember 12, 2023 | finance.yahoo.comPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology ProviderDecember 12, 2023 | finance.yahoo.comPetros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC StatusDecember 9, 2023 | nasdaq.comMaxim Group Initiates Coverage of Petros Pharmaceuticals (PTPI) with Buy RecommendationDecember 9, 2023 | benzinga.comPetros Pharma Stock (NASDAQ:PTPI), Analyst Ratings, Price Targets, PredictionsDecember 8, 2023 | realmoney.thestreet.comPetros Pharmaceuticals initiated with bullish view at MaximDecember 7, 2023 | morningstar.comPetros Pharmaceuticals Inc Ordinary SharesDecember 5, 2023 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology ProviderDecember 5, 2023 | finance.yahoo.comPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology ProviderOctober 30, 2023 | finance.yahoo.comPetros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)October 19, 2023 | finance.yahoo.comFollowing Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRAOctober 4, 2023 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelSee More Headlines Receive PTPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTPI CUSIPN/A CIK1815903 Webwww.petrospharma.com Phone973-242-0005FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+525.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($6.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,160,000.00 Net Margins-181.87% Pretax Margin-140.21% Return on Equity-68.90% Return on Assets-24.74% Debt Debt-to-Equity Ratio0.57 Current Ratio1.89 Quick Ratio1.74 Sales & Book Value Annual Sales$5.82 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.16Miscellaneous Outstanding Shares6,880,000Free Float4,375,000Market Cap$4.40 million OptionableNot Optionable Beta1.91 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John David Shulman (Age 61)Executive Chairman of the Board Mr. Fady Boctor M.B.A. (Age 46)President & Chief Commercial Officer Comp: $681.97kMr. Mitchell S. Arnold M.B.A. (Age 60)VP of Finance & Chief Accounting Officer Comp: $465.68kKey CompetitorsExicureNASDAQ:XCURNexImmuneNASDAQ:NEXIProcessa PharmaceuticalsNASDAQ:PCSALongeveronNASDAQ:LGVNChina PharmaNYSE:CPHIView All Competitors PTPI Stock Analysis - Frequently Asked Questions Should I buy or sell Petros Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Petros Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTPI shares. View PTPI analyst ratings or view top-rated stocks. What is Petros Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued 1-year target prices for Petros Pharmaceuticals' stock. Their PTPI share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 525.1% from the stock's current price. View analysts price targets for PTPI or view top-rated stocks among Wall Street analysts. How have PTPI shares performed in 2024? Petros Pharmaceuticals' stock was trading at $1.41 on January 1st, 2024. Since then, PTPI shares have decreased by 54.6% and is now trading at $0.6399. View the best growth stocks for 2024 here. Are investors shorting Petros Pharmaceuticals? Petros Pharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 69,800 shares, a decline of 52.3% from the March 31st total of 146,200 shares. Based on an average daily trading volume, of 944,200 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.7% of the shares of the company are sold short. View Petros Pharmaceuticals' Short Interest. When is Petros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PTPI earnings forecast. How were Petros Pharmaceuticals' earnings last quarter? Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) posted its quarterly earnings results on Monday, April, 1st. The company reported ($2.17) EPS for the quarter. The business earned ($0.36) million during the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative trailing twelve-month return on equity of 68.90%. When did Petros Pharmaceuticals' stock split? Petros Pharmaceuticals shares reverse split on Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Petros Pharmaceuticals? Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTPI) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
